Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
EXACT Trial: Results of the Phase 1 Dose-Escalation Study.
Journal: Circulation. Cardiovascular interventions
Published: July 28, 2023
Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.
Journal: PloS one
Published: November 01, 2016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.
Journal: Journal of the American Heart Association
Published: June 23, 2016
Darapladib for preventing ischemic events in stable coronary heart disease.
Journal: The New England journal of medicine
Published: April 01, 2014
Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging.
Journal: Journal of the American College of Cardiology
Published: April 12, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026